<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Ganoderma lucidum</italic> supplementation resulted in a stable disease condition in 35.1% of the study population suffering from lung cancer at the 12 week’s visit (
 <xref rid="B19" ref-type="bibr">Gao et al., 2003a</xref>). This was significantly higher than in the control group (22.6%). Moreover, a significant increase in lymphocyte mitogenic reactivity to concanavalin A (baseline: 52.3 ± 11.5, after treatment: 68.9 ± 8.9, 
 <italic>p</italic> &lt; 0.05), CD3 percentage (baseline: 46.2 ± 11.3, after treatment: 55.8 ± 10.5, 
 <italic>p</italic> &lt; 0.05) and natural killer cell activity (baseline: 24.1 ± 12.3, after treatment: 42.8 ± 19.7, 
 <italic>p</italic> &lt; 0.05) was shown; a marginal increase in CD4 percentage and CD4/CD8 ratio; but a marginal decrease in CD8. All of these immune parameters remained unchanged or decreased in the control group.
</p>
